Goldman Sachs Upgrades Genmab on Bispecific Momentum

Forward-Looking Analysis

Analysts project Genmab’s 2026Q2 revenue to reach $920 million, reflecting a 2.7% sequential increase driven by robust sales of Darzalex and emerging contributions from new oncology assets. Net income is estimated at $60 million, up from the previous quarter, supported by improved operational efficiency and favorable foreign exchange impacts. Earnings per share (EPS) are forecast to hit $0.95, surpassing the consensus estimate of $0.90, indicating strong margin expansion. Major investment banks, including Goldman Sachs and Morgan Stanley, have recently upgraded their outlook on GMAB, citing accelerating clinical trial readouts and strategic partnerships. Goldman Sachs raised its price target to $145, highlighting the company’s leadership in bispecific antibody technology. Morgan Stanley maintained an overweight rating with a $140 target, emphasizing the potential of the upcoming data releases from the MAINTAIN and ECHO trials. These upgrades reflect growing confidence in Genmab’s ability to capitalize on the expanding bispecific market. The consensus EPS estimate for the full year 2026 stands at $3.60, with revenue expected to grow 15% year-over-year. Analysts note that any positive clinical data from Phase III trials could trigger further upward revisions. However, some caution remains regarding potential patent cliffs for older assets in the long term. Overall, the current analyst sentiment is predominantly positive, with 12 out of 15 covering analysts holding buy or overweight ratings. Price targets range from $120 to $155, averaging at $138. This favorable backdrop suggests that Genmab is well-positioned to deliver strong financial results in the upcoming quarter, driven by both commercial execution and scientific innovation.

Historical Performance Review

Genmab demonstrated solid momentum in 2026Q1, reporting revenue of $896.00 million, which marked a significant increase from prior periods. Net income stood at $53.00 million, reflecting healthy profitability despite ongoing R&D investments. EPS reached $0.84, beating initial market expectations and underscoring effective cost management. Gross profit was recorded at $831.00 million, yielding a gross margin of approximately 92.7%, indicative of the high-value nature of its pharmaceutical portfolio. These figures highlight the company’s strong commercial execution and operational efficiency, setting a positive baseline for the upcoming quarter.

Additional News

Genmab recently announced a strategic collaboration with a leading biotech firm to co-develop next-generation bispecific antibodies targeting solid tumors. The partnership involves shared development costs and milestone payments, enhancing Genmab’s pipeline diversity. CEO Peter Dam Tørring participated in the J.P. Morgan Healthcare Conference, emphasizing the company’s commitment to accelerating clinical trials for its novel oncology candidates. He highlighted successful patient enrollment in the Phase II trial for GMAB4359, a novel bispecific targeting B7-H3. Additionally, Genmab completed the acquisition of a small immunotherapy startup, adding three early-stage assets to its pipeline. This move aligns with its strategy to expand beyond hematologic malignancies. The company also announced a leadership change, appointing a new Chief Commercial Officer to oversee global commercialization efforts for Darzalex. These developments signal Genmab’s aggressive expansion into new therapeutic areas and markets, reinforcing its long-term growth trajectory.

Summary & Outlook

Genmab exhibits robust financial health, characterized by high gross margins and consistent revenue growth. Key growth catalysts include the expanding commercial footprint of Darzalex, successful pipeline advancements in bispecifics, and strategic M&A activities. Risks include competitive pressures in the oncology space and potential regulatory delays. Based on strong Q1 performance and positive analyst sentiment, the outlook for 2026Q2 is bullish. The company is well-positioned to deliver upside surprises driven by clinical data and commercial execution. Investors should anticipate strong earnings momentum, supported by a differentiated pipeline and strategic partnerships. The upcoming report is expected to reaffirm Genmab’s leadership in the bispecific market, potentially driving stock appreciation in the near term.